Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 644

1.

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.

Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM.

J Immunother Cancer. 2020 Mar;8(1). pii: e000337. doi: 10.1136/jitc-2019-000337. Review.

2.

Immunotherapy, Inflammation and Colorectal Cancer.

Lichtenstern CR, Ngu RK, Shalapour S, Karin M.

Cells. 2020 Mar 4;9(3). pii: E618. doi: 10.3390/cells9030618. Review.

3.

The role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC.

Käsmann L, Taugner J, Eze C, Roengvoraphoj O, Dantes M, Gennen K, Karin M, Tufman A, Belka C, Manapov F.

Ann Oncol. 2019 Apr;30 Suppl 2:ii36. doi: 10.1093/annonc/mdz067.011. No abstract available.

4.

Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis.

Taugner J, Käsmann L, Eze C, Dantes M, Roengvoraphoj O, Gennen K, Karin M, Tufman A, Belka C, Manapov F.

Ann Oncol. 2019 Apr;30 Suppl 2:ii35. doi: 10.1093/annonc/mdz067.009. No abstract available.

5.

NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly.

He F, Antonucci L, Yamachika S, Zhang Z, Taniguchi K, Umemura A, Hatzivassiliou G, Roose-Girma M, Reina-Campos M, Duran A, Diaz-Meco MT, Moscat J, Sun B, Karin M.

J Hepatol. 2020 Feb 24. pii: S0168-8278(20)30070-2. doi: 10.1016/j.jhep.2020.01.023. [Epub ahead of print]

PMID:
32105670
6.

Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice.

Xu J, Ma HY, Liu X, Rosenthal S, Baglieri J, McCubbin R, Sun M, Koyama Y, Geoffroy CG, Saijo K, Shang L, Nishio T, Maricic I, Kreifeldt M, Kusumanchi P, Roberts A, Zheng B, Kumar V, Zengler K, Pizzo DP, Hosseini M, Contet C, Glass CK, Liangpunsakul S, Tsukamoto H, Gao B, Karin M, Brenner DA, Koob GF, Kisseleva T.

JCI Insight. 2020 Feb 13;5(3). pii: 131277. doi: 10.1172/jci.insight.131277.

7.

Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers.

Shalapour S, Karin M.

Annu Rev Immunol. 2020 Feb 7. doi: 10.1146/annurev-immunol-082019-081656. [Epub ahead of print]

PMID:
32040356
8.

An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.

Zhao P, Sun X, Chaggan C, Liao Z, In Wong K, He F, Singh S, Loomba R, Karin M, Witztum JL, Saltiel AR.

Science. 2020 Feb 7;367(6478):652-660. doi: 10.1126/science.aay0542.

PMID:
32029622
9.

NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia.

Sanchez-Lopez E, Ghia EM, Antonucci L, Sharma N, Rassenti LZ, Xu J, Sun B, Kipps TJ, Karin M.

Cell Death Differ. 2020 Jan 28. doi: 10.1038/s41418-020-0496-1. [Epub ahead of print]

PMID:
31992855
10.

A dual role for hepatocyte-intrinsic canonical NF-κB signaling in virus control.

Namineni S, O'Connor T, Faure-Dupuy S, Johansen P, Riedl T, Liu K, Xu H, Singh I, Shinde P, Li F, Pandyra A, Sharma P, Ringelhan M, Muschaweckh A, Borst K, Blank P, Lampl S, Durantel D, Farhat R, Weber A, Lenggenhager D, Kündig TM, Staeheli P, Protzer U, Wohlleber D, Holzmann B, Binder M, Breuhahn K, Assmus LM, Nattermann J, Abdullah Z, Rolland M, Dejardin E, Lang PA, Lang KS, Karin M, Lucifora J, Kalinke U, Knolle PA, Heikenwalder M.

J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30010-6. doi: 10.1016/j.jhep.2019.12.019. [Epub ahead of print]

11.

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia.

Schmidt T, Kharabi Masouleh B, Loges S, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, De Keersmaecker K, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, De Mol M, Beel K, Dias S, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G, Dewerchin M, Carmeliet P.

Cancer Cell. 2020 Jan 13;37(1):135-136. doi: 10.1016/j.ccell.2019.12.010. No abstract available.

PMID:
31935370
12.

Sestrins are evolutionarily conserved mediators of exercise benefits.

Kim M, Sujkowski A, Namkoong S, Gu B, Cobb T, Kim B, Kowalsky AH, Cho CS, Semple I, Ro SH, Davis C, Brooks SV, Karin M, Wessells RJ, Lee JH.

Nat Commun. 2020 Jan 13;11(1):190. doi: 10.1038/s41467-019-13442-5.

13.

Sestrin prevents atrophy of disused and aging muscles by integrating anabolic and catabolic signals.

Segalés J, Perdiguero E, Serrano AL, Sousa-Victor P, Ortet L, Jardí M, Budanov AV, Garcia-Prat L, Sandri M, Thomson DM, Karin M, Hee Lee J, Muñoz-Cánoves P.

Nat Commun. 2020 Jan 13;11(1):189. doi: 10.1038/s41467-019-13832-9.

14.

IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.

Ma HY, Yamamoto G, Xu J, Liu X, Karin D, Kim JY, Alexandrov LB, Koyama Y, Nishio T, Benner C, Heinz S, Rosenthal SB, Liang S, Sun M, Karin G, Zhao P, Brodt P, Mckillop IH, Quehenberger O, Dennis E, Saltiel A, Tsukamoto H, Gao B, Karin M, Brenner DA, Kisseleva T.

J Hepatol. 2019 Dec 31. pii: S0168-8278(19)30761-5. doi: 10.1016/j.jhep.2019.12.016. [Epub ahead of print]

PMID:
31899206
15.

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.

Gennen K, Käsmann L, Taugner J, Eze C, Karin M, Roengvoraphoj O, Neumann J, Tufman A, Orth M, Reu S, Belka C, Manapov F.

Radiat Oncol. 2020 Jan 2;15(1):5. doi: 10.1186/s13014-019-1453-3.

16.

Correction: Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson L, Karasic T, Llovet J, Finn R, Groopman J, El-Serag H, Monga S, Wang XW, Karin M, Schwartz R, Tanabe K, Roberts L, Gunaratne P, Tsung A, Brown K, Lawrence T, Salem R, Singal A, Kim A, Rabiee A, Resar L, Meyer J, Hoshida Y, He AR, Ghoshal K, Ryan P, Jaffee E, Guha C, Mishra L, Coleman N, Ahmed M.

Cancer Res. 2019 Nov 15;79(22):5897. doi: 10.1158/0008-5472.CAN-19-2958. No abstract available.

17.

Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.

Taugner J, Käsmann L, Eze C, Dantes M, Roengvoraphoj O, Gennen K, Karin M, Petruknov O, Tufman A, Belka C, Manapov F.

Transl Lung Cancer Res. 2019 Oct;8(5):593-604. doi: 10.21037/tlcr.2019.09.19.

18.

Intermittent hypoxia and hypercapnia induces inhibitor of nuclear factor-κB kinase subunit β-dependent atherosclerosis in pulmonary arteries.

Imamura T, Xue J, Poulsen O, Zhou D, Karin M, Haddad GG.

Am J Physiol Regul Integr Comp Physiol. 2019 Dec 1;317(6):R763-R769. doi: 10.1152/ajpregu.00056.2019. Epub 2019 Oct 16.

PMID:
31618063
19.

RIPK1 Mediates TNF-Induced Intestinal Crypt Apoptosis During Chronic NF-κB Activation.

Wong J, Garcia-Carbonell R, Zelic M, Ho SB, Boland BS, Yao SJ, Desai SA, Das S, Planell N, Harris PA, Font-Burgada J, Taniguchi K, Bertin J, Salas A, Pasparakis M, Gough PJ, Kelliher M, Karin M, Guma M.

Cell Mol Gastroenterol Hepatol. 2020;9(2):295-312. doi: 10.1016/j.jcmgh.2019.10.002. Epub 2019 Oct 10.

20.

Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.

Käsmann L, Taugner J, Eze C, Roengvoraphoj O, Dantes M, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C, Manapov F.

Anticancer Res. 2019 Sep;39(9):5077-5081. doi: 10.21873/anticanres.13701.

PMID:
31519618

Supplemental Content

Loading ...
Support Center